Animal studies with botulinum toxins may produce misleading results

Anesthesia and Analgesia

Volumn 115, Issue 3, 2012, Pages 736-

  Pickett, Andy ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

CLINICAL PRACTICE; DIFFUSION; DOSE RESPONSE; DRUG SENSITIVITY; EXPERIMENTAL STUDY; HINDLIMB; LETTER; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE;

ANIMALS; BOTULINUM TOXINS; MALE; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NEUROMUSCULAR BLOCKING AGENTS; SYNAPTIC TRANSMISSION;

EID: 84865700881     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318263c8ce     Document Type: Letter

References (7)

1. Frick CG, Fink H, Blobner M, Martyn J. A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites. Anesth Analg 2012;114:102-9
2. Based on a 75-kg average human weight (164.7 lb. for US women aged 20 and over). Available at: http://www.cdc. gov/nchs/fastats/bodymeas.htm. Accessed January 15, 2012
3. Poulain B, Popoff MR, Molgo J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008;1:14-87
4. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13:2-10
5. Pickett A, O'Keeffe R, Judge A, Dodd S. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon 2008;52: 455-64
6. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 2009;25:1573-84
7. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009;35:1-8